- Home
- ELWS vs IBIO Comparison
ELWS vs IBIO Comparison
Compare ELWS & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELWS | IBIO |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 16.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELWS | IBIO |
|---|---|---|
| Price | $5.51 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 24.9K | ★ 13.0M |
| Earning Date | 12-31-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,083,071.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 145.52 | ★ 185.71 |
| 52 Week Low | $1.64 | $0.56 |
| 52 Week High | $10.50 | $6.89 |
Technical Indicators
Market Signals| Indicator | ELWS | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 58.42 |
| Support Level | $5.38 | $0.98 |
| Resistance Level | $6.11 | $3.82 |
| Average True Range (ATR) | 0.30 | 0.38 |
| MACD | -0.06 | 0.10 |
| Stochastic Oscillator | 39.81 | 34.33 |
Price Performance
Historical ComparisonAbout ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.